Partners are central to Amarna's plans to deliver the significant clinical and commercial potential of its SVac platform."

Our Partnering Strategy

Amarna is committed to working with a range of partners to develop novel solutions across several therapeutic areas based on its innovative viral vector platform SVac. We are focused on developing a pipeline of novel SVac-based drug candidates for auto-immune diseases, genetic disorders, cancer and viral infectious diseases.

We welcome interest from pharmaceutical and biotech companies seeking access to our unique viral vector platform. Through collaboration with Amarna, we aim to fulfill the great promise in genomics by using SVac to develop better biologics in areas of high unmet need.

In addition, we also offer our PRP3 production platform technology for companies wishing to manufacture clinically and cost effective, clinical grade therapeutic proteins quickly and efficiently.

For more opportunities on partnering or out licensing opportunities, please contact:

Stephan Hermening PhD
Director Business Development

tel: +31 71 3322194
mob: +31 6 20011812

Amarna has established agreements with a range of key commercial and academic partners to exploit the full value of SVac and to help develop Amarna’s proprietary pipeline.